Gilead Sciences has achieved FDA approval for next-generation CAR T-cell therapies, leveraging the platform influenced by Trump-era tariffs and onshoring trends.
5 reports, 3 independent
Updated Sep 6
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 5
- Developments
- 4
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences has achieved FDA approval for next-generation CAR T-cell therapies, leveraging the platform influenced by Trump-era tariffs and onshoring trends.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- CVS Health's adherence to ACA mandates impacts Gilead's drug uptake following FDA approval for Yeztugo.Sub-event
Gilead gains FDA approval for next-gen CAR T-cell therapies, influenced by Trump-era policies.1 source
Gilead announces a manufacturing hub at its headquarters, aligning with Trump's push for domestic production.1 source
- Gilead benefits from Trump-era tariffs, advancing clinical trials and attracting investment.
Keep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
- FDA
Related events
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- Baylor College of Medicine researchers participated in a study on CAR T-cell therapy, co-authored by Andras Heczey.
- FDA is currently reviewing cell therapy products like Breyanzi®, seeking approval for CAR-T cell therapies, but noted insufficient information to establish a link.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
Coverage
Newest first; wire copies grouped- Insider MonkeyGilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy Gilead Sciences Inc. (NASDAQ:GILD) is one of the best growth stocks to buy for the next 2 years. On August 22, Gilead Science
- ReutersGilead starts building manufacturing hub under $32 billion planned US investments (Reuters) -Gilead Sciences said on Wednesday it has started work on a new pharmaceutical development and manufacturin
- Insider MonkeyAnalyst Says Gilead (GILD) is a ‘Very High Quality’ Cheap Stock – Here’s Why We recently published Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings. Gilead Sciences Inc (NASDAQ:GILD) is one o
- ZacksGILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU Gilead Sciences, Inc. (GILD) announced that the European Commission (“EC”) has granted marketing authorization to HIV prevention drug
- Unknown outlet